Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study ...

Radiotherapy had a distinct advantage over surgery in reducing myeloma progression while maintaining comparable survival ...

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.

Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.